Results 111 to 120 of about 14,309 (181)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. [PDF]

BMC Pharmacol Toxicol, 2018
Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, Góes ACMA, Batoreu NM, Maia MLS, Albuquerque EM, Matos DCS, Saura PL.   +11 more
europepmc   +1 more source

Recombinant Interferon Alfa-2b [PDF]

, 2020
openaire   +1 more source

Interferon alfa-2b Regimen [PDF]

, 2020
openaire   +1 more source

Bevacizumab/Interferon Alfa Regimen [PDF]

, 2020
openaire   +1 more source

Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia. [PDF]

Am J Ophthalmol, 2019
Venkateswaran N, Mercado C, Galor A, Karp CL.   +3 more
europepmc   +1 more source

Recombinant Interferon Alfa-2a [PDF]

, 2020
openaire   +1 more source

Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old? [PDF]

Ann Transl Med, 2019
Zibelman M, Plimack ER.
europepmc   +1 more source

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. [PDF]

J Clin Oncol, 2018
Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM.   +18 more
europepmc   +1 more source

Interferon-Alfa as a Vaccine Adjuvant [PDF]

, 2015
openaire   +1 more source

Interferon alfa-induced sarcoidosis resolving without drug withdrawal. [PDF]

JAAD Case Rep, 2016
Ortiz Salvador JM, Victoria Martínez AM, Ferrer DS, Alegre de Miquel V, Pérez Ferriols A.   +4 more
europepmc   +1 more source